Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by celine.gongora
Group name EquipeCG
Item Type Journal Article
Title The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor
Creator Creusot et al.
Author Nicolas Creusot
Author Matthieu Gassiot
Author Elina Alaterre
Author Barbara Chiavarina
Author Marina Grimaldi
Author Abdelhay Boulahtouf
Author Lucia Toporova
Author Sabine Gerbal-Chaloin
Author Martine Daujat-Chavanieu
Author Alice Matheux
Author Roger Rahmani
Author Céline Gongora
Author Alexandre Evrard
Author Philippe Pourquier
Author Patrick Balaguer
Abstract The human pregnane X receptor (hPXR) is activated by a large set of endogenous and exogenous compounds and plays a critical role in the control of detoxifying enzymes and transporters regulating liver and gastrointestinal drug metabolism and clearance. hPXR is also involved in both the development of multidrug resistance and enhanced cancer cells aggressiveness. Moreover, its unintentional activation by pharmaceutical drugs can mediate drug-drug interactions and cause severe adverse events. In that context, the potential of the anticancer BRAF inhibitor dabrafenib suspected to activate hPXR and the human constitutive androstane receptor (hCAR) has not been thoroughly investigated yet. Using different reporter cellular assays, we demonstrate that dabrafenib can activate hPXR as efficiently as its reference agonist SR12813, whereas it does not activate mouse or zebrafish PXR nor hCAR. We also showed that dabrafenib binds to recombinant hPXR, induces the expression of hPXR responsive genes in colon LS174T-hPXR cancer cells and human hepatocytes and finally increases the proliferation in LS174T-hPXR cells. Our study reveals that by using a panel of different cellular techniques it is possible to improve the assessment of hPXR agonist activity for new developed drugs.
Publication Cells
Volume 9
Issue 7
Pages E1641
Date 2020-07-08
Journal Abbr Cells
Language eng
DOI 10.3390/cells9071641
ISSN 2073-4409
Library Catalog PubMed
Extra PMID: 32650447 PMCID: PMC7407672
Tags Antineoplastic Agents, Cell Line, Tumor, Cell Proliferation, colon and liver cancer cells, corresponding, dabrafenib, HeLa Cells, Hep G2 Cells, hPXR, Humans, Imidazoles, original, Oximes, Pregnane X Receptor, proliferation, Protein Binding
Date Added 2022/08/29 - 15:27:56
Date Modified 2022/08/29 - 16:23:42
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés